0
     

Report Added
Report already added
Non-small Cell Lung Cancer Therapeutics Market - Global Outlook and Forecast 2022-2028

Non-small Cell Lung Cancer Therapeutics Market - Global Outlook and Forecast 2022-2028

This report contains market size and forecasts of Non-small Cell Lung Cancer Therapeutics in Global, including the following market information:

Global Non-small Cell Lung Cancer Therapeutics Market Revenue, 2017-2022, 2023-2028, ($ millions)
Global top five companies in 2021 (%)
The global Non-small Cell Lung Cancer Therapeutics market was valued at 9329.4 million in 2021 and is projected to reach US$ 14060 million by 2028, at a CAGR of 6.0% during the forecast period.
The U.S. Market is Estimated at $ Million in 2021, While China is Forecast to Reach $ Million by 2028.
Alimta Segment to Reach $ Million by 2028, with a % CAGR in next six years.
The global key manufacturers of Non-small Cell Lung Cancer Therapeutics include GlaxoSmithKline, Novartis, AstraZeneca, Roche, Bristol-Myers Squibb, Pfizer, Eli Lilly and Sanofi, etc. In 2021, the global top five players have a share approximately % in terms of revenue.
MARKET MONITOR GLOBAL, INC (MMG) has surveyed the Non-small Cell Lung Cancer Therapeutics companies, and industry experts on this industry, involving the revenue, demand, product type, recent developments and plans, industry trends, drivers, challenges, obstacles, and potential risks.

Total Market by Segment:
Global Non-small Cell Lung Cancer Therapeutics Market, by Type, 2017-2022, 2023-2028 ($ millions)
Global Non-small Cell Lung Cancer Therapeutics Market Segment Percentages, by Type, 2021 (%)
Alimta
Iressa
Avastin
Tarceva
Zykadia
Tagrisso
Xalkori
Cyramza
Opdivo
Alecensa
Global Non-small Cell Lung Cancer Therapeutics Market, by Application, 2017-2022, 2023-2028 ($ millions)
Global Non-small Cell Lung Cancer Therapeutics Market Segment Percentages, by Application, 2021 (%)
Hospital
Clinic
Global Non-small Cell Lung Cancer Therapeutics Market, By Region and Country, 2017-2022, 2023-2028 ($ Millions)
Global Non-small Cell Lung Cancer Therapeutics Market Segment Percentages, By Region and Country, 2021 (%)
North America
US
Canada
Mexico
Europe
Germany
France
U.K.
Italy
Russia
Nordic Countries
Benelux
Rest of Europe
Asia
China
Japan
South Korea
Southeast Asia
India
Rest of Asia
South America
Brazil
Argentina
Rest of South America
Middle East & Africa
Turkey
Israel
Saudi Arabia
UAE
Rest of Middle East & Africa

Competitor Analysis
The report also provides analysis of leading market participants including:
Key companies Non-small Cell Lung Cancer Therapeutics revenues in global market, 2017-2022 (estimated), ($ millions)
Key companies Non-small Cell Lung Cancer Therapeutics revenues share in global market, 2021 (%)
Further, the report presents profiles of competitors in the market, key players include:
GlaxoSmithKline
Novartis
AstraZeneca
Roche
Bristol-Myers Squibb
Pfizer
Eli Lilly
Sanofi
Table of Contents

1 Introduction to Research & Analysis Reports
1.1 Non-small Cell Lung Cancer Therapeutics Market Definition
1.2 Market Segments
1.2.1 Market by Type
1.2.2 Market by Application
1.3 Global Non-small Cell Lung Cancer Therapeutics Market Overview
1.4 Features & Benefits of This Report
1.5 Methodology & Sources of Information
1.5.1 Research Methodology
1.5.2 Research Process
1.5.3 Base Year
1.5.4 Report Assumptions & Caveats
2 Global Non-small Cell Lung Cancer Therapeutics Overall Market Size
2.1 Global Non-small Cell Lung Cancer Therapeutics Market Size: 2021 VS 2028
2.2 Global Non-small Cell Lung Cancer Therapeutics Market Size, Prospects & Forecasts: 2017-2028
2.3 Key Market Trends, Opportunity, Drivers and Restraints
2.3.1 Market Opportunities & Trends
2.3.2 Market Drivers
2.3.3 Market Restraints
3 Company Landscape
3.1 Top Non-small Cell Lung Cancer Therapeutics Players in Global Market
3.2 Top Global Non-small Cell Lung Cancer Therapeutics Companies Ranked by Revenue
3.3 Global Non-small Cell Lung Cancer Therapeutics Revenue by Companies
3.4 Top 3 and Top 5 Non-small Cell Lung Cancer Therapeutics Companies in Global Market, by Revenue in 2021
3.5 Global Companies Non-small Cell Lung Cancer Therapeutics Product Type
3.6 Tier 1, Tier 2 and Tier 3 Non-small Cell Lung Cancer Therapeutics Players in Global Market
3.6.1 List of Global Tier 1 Non-small Cell Lung Cancer Therapeutics Companies
3.6.2 List of Global Tier 2 and Tier 3 Non-small Cell Lung Cancer Therapeutics Companies
4 Market Sights by Product
4.1 Overview
4.1.1 by Type - Global Non-small Cell Lung Cancer Therapeutics Market Size Markets, 2021 & 2028
4.1.2 Alimta
4.1.3 Iressa
4.1.4 Avastin
4.1.5 Tarceva
4.1.6 Zykadia
4.1.7 Tagrisso
4.1.8 Xalkori
4.1.9 Cyramza
4.1.10 Opdivo
4.1.11 Alecensa
4.2 By Type - Global Non-small Cell Lung Cancer Therapeutics Revenue & Forecasts
4.2.1 By Type - Global Non-small Cell Lung Cancer Therapeutics Revenue, 2017-2022
4.2.2 By Type - Global Non-small Cell Lung Cancer Therapeutics Revenue, 2023-2028
4.2.3 By Type - Global Non-small Cell Lung Cancer Therapeutics Revenue Market Share, 2017-2028
5 Sights by Application
5.1 Overview
5.1.1 By Application - Global Non-small Cell Lung Cancer Therapeutics Market Size, 2021 & 2028
5.1.2 Hospital
5.1.3 Clinic
5.2 By Application - Global Non-small Cell Lung Cancer Therapeutics Revenue & Forecasts
5.2.1 By Application - Global Non-small Cell Lung Cancer Therapeutics Revenue, 2017-2022
5.2.2 By Application - Global Non-small Cell Lung Cancer Therapeutics Revenue, 2023-2028
5.2.3 By Application - Global Non-small Cell Lung Cancer Therapeutics Revenue Market Share, 2017-2028
6 Sights by Region
6.1 By Region - Global Non-small Cell Lung Cancer Therapeutics Market Size, 2021 & 2028
6.2 By Region - Global Non-small Cell Lung Cancer Therapeutics Revenue & Forecasts
6.2.1 By Region - Global Non-small Cell Lung Cancer Therapeutics Revenue, 2017-2022
6.2.2 By Region - Global Non-small Cell Lung Cancer Therapeutics Revenue, 2023-2028
6.2.3 By Region - Global Non-small Cell Lung Cancer Therapeutics Revenue Market Share, 2017-2028
6.3 North America
6.3.1 By Country - North America Non-small Cell Lung Cancer Therapeutics Revenue, 2017-2028
6.3.2 US Non-small Cell Lung Cancer Therapeutics Market Size, 2017-2028
6.3.3 Canada Non-small Cell Lung Cancer Therapeutics Market Size, 2017-2028
6.3.4 Mexico Non-small Cell Lung Cancer Therapeutics Market Size, 2017-2028
6.4 Europe
6.4.1 By Country - Europe Non-small Cell Lung Cancer Therapeutics Revenue, 2017-2028
6.4.2 Germany Non-small Cell Lung Cancer Therapeutics Market Size, 2017-2028
6.4.3 France Non-small Cell Lung Cancer Therapeutics Market Size, 2017-2028
6.4.4 U.K. Non-small Cell Lung Cancer Therapeutics Market Size, 2017-2028
6.4.5 Italy Non-small Cell Lung Cancer Therapeutics Market Size, 2017-2028
6.4.6 Russia Non-small Cell Lung Cancer Therapeutics Market Size, 2017-2028
6.4.7 Nordic Countries Non-small Cell Lung Cancer Therapeutics Market Size, 2017-2028
6.4.8 Benelux Non-small Cell Lung Cancer Therapeutics Market Size, 2017-2028
6.5 Asia
6.5.1 By Region - Asia Non-small Cell Lung Cancer Therapeutics Revenue, 2017-2028
6.5.2 China Non-small Cell Lung Cancer Therapeutics Market Size, 2017-2028
6.5.3 Japan Non-small Cell Lung Cancer Therapeutics Market Size, 2017-2028
6.5.4 South Korea Non-small Cell Lung Cancer Therapeutics Market Size, 2017-2028
6.5.5 Southeast Asia Non-small Cell Lung Cancer Therapeutics Market Size, 2017-2028
6.5.6 India Non-small Cell Lung Cancer Therapeutics Market Size, 2017-2028
6.6 South America
6.6.1 By Country - South America Non-small Cell Lung Cancer Therapeutics Revenue, 2017-2028
6.6.2 Brazil Non-small Cell Lung Cancer Therapeutics Market Size, 2017-2028
6.6.3 Argentina Non-small Cell Lung Cancer Therapeutics Market Size, 2017-2028
6.7 Middle East & Africa
6.7.1 By Country - Middle East & Africa Non-small Cell Lung Cancer Therapeutics Revenue, 2017-2028
6.7.2 Turkey Non-small Cell Lung Cancer Therapeutics Market Size, 2017-2028
6.7.3 Israel Non-small Cell Lung Cancer Therapeutics Market Size, 2017-2028
6.7.4 Saudi Arabia Non-small Cell Lung Cancer Therapeutics Market Size, 2017-2028
6.7.5 UAE Non-small Cell Lung Cancer Therapeutics Market Size, 2017-2028
7 Players Profiles
7.1 GlaxoSmithKline
7.1.1 GlaxoSmithKline Corporate Summary
7.1.2 GlaxoSmithKline Business Overview
7.1.3 GlaxoSmithKline Non-small Cell Lung Cancer Therapeutics Major Product Offerings
7.1.4 GlaxoSmithKline Non-small Cell Lung Cancer Therapeutics Revenue in Global Market (2017-2022)
7.1.5 GlaxoSmithKline Key News
7.2 Novartis
7.2.1 Novartis Corporate Summary
7.2.2 Novartis Business Overview
7.2.3 Novartis Non-small Cell Lung Cancer Therapeutics Major Product Offerings
7.2.4 Novartis Non-small Cell Lung Cancer Therapeutics Revenue in Global Market (2017-2022)
7.2.5 Novartis Key News
7.3 AstraZeneca
7.3.1 AstraZeneca Corporate Summary
7.3.2 AstraZeneca Business Overview
7.3.3 AstraZeneca Non-small Cell Lung Cancer Therapeutics Major Product Offerings
7.3.4 AstraZeneca Non-small Cell Lung Cancer Therapeutics Revenue in Global Market (2017-2022)
7.3.5 AstraZeneca Key News
7.4 Roche
7.4.1 Roche Corporate Summary
7.4.2 Roche Business Overview
7.4.3 Roche Non-small Cell Lung Cancer Therapeutics Major Product Offerings
7.4.4 Roche Non-small Cell Lung Cancer Therapeutics Revenue in Global Market (2017-2022)
7.4.5 Roche Key News
7.5 Bristol-Myers Squibb
7.5.1 Bristol-Myers Squibb Corporate Summary
7.5.2 Bristol-Myers Squibb Business Overview
7.5.3 Bristol-Myers Squibb Non-small Cell Lung Cancer Therapeutics Major Product Offerings
7.5.4 Bristol-Myers Squibb Non-small Cell Lung Cancer Therapeutics Revenue in Global Market (2017-2022)
7.5.5 Bristol-Myers Squibb Key News
7.6 Pfizer
7.6.1 Pfizer Corporate Summary
7.6.2 Pfizer Business Overview
7.6.3 Pfizer Non-small Cell Lung Cancer Therapeutics Major Product Offerings
7.6.4 Pfizer Non-small Cell Lung Cancer Therapeutics Revenue in Global Market (2017-2022)
7.6.5 Pfizer Key News
7.7 Eli Lilly
7.7.1 Eli Lilly Corporate Summary
7.7.2 Eli Lilly Business Overview
7.7.3 Eli Lilly Non-small Cell Lung Cancer Therapeutics Major Product Offerings
7.7.4 Eli Lilly Non-small Cell Lung Cancer Therapeutics Revenue in Global Market (2017-2022)
7.7.5 Eli Lilly Key News
7.8 Sanofi
7.8.1 Sanofi Corporate Summary
7.8.2 Sanofi Business Overview
7.8.3 Sanofi Non-small Cell Lung Cancer Therapeutics Major Product Offerings
7.8.4 Sanofi Non-small Cell Lung Cancer Therapeutics Revenue in Global Market (2017-2022)
7.8.5 Sanofi Key News
8 Conclusion
9 Appendix
9.1 Note
9.2 Examples of Clients
9.3 Disclaimer

List of Tables
Table 1. Non-small Cell Lung Cancer Therapeutics Market Opportunities & Trends in Global Market
Table 2. Non-small Cell Lung Cancer Therapeutics Market Drivers in Global Market
Table 3. Non-small Cell Lung Cancer Therapeutics Market Restraints in Global Market
Table 4. Key Players of Non-small Cell Lung Cancer Therapeutics in Global Market
Table 5. Top Non-small Cell Lung Cancer Therapeutics Players in Global Market, Ranking by Revenue (2021)
Table 6. Global Non-small Cell Lung Cancer Therapeutics Revenue by Companies, (US$, Mn), 2017-2022
Table 7. Global Non-small Cell Lung Cancer Therapeutics Revenue Share by Companies, 2017-2022
Table 8. Global Companies Non-small Cell Lung Cancer Therapeutics Product Type
Table 9. List of Global Tier 1 Non-small Cell Lung Cancer Therapeutics Companies, Revenue (US$, Mn) in 2021 and Market Share
Table 10. List of Global Tier 2 and Tier 3 Non-small Cell Lung Cancer Therapeutics Companies, Revenue (US$, Mn) in 2021 and Market Share
Table 11. By Type – Global Non-small Cell Lung Cancer Therapeutics Revenue, (US$, Mn), 2021 & 2028
Table 12. By Type - Non-small Cell Lung Cancer Therapeutics Revenue in Global (US$, Mn), 2017-2022
Table 13. By Type - Non-small Cell Lung Cancer Therapeutics Revenue in Global (US$, Mn), 2023-2028
Table 14. By Application – Global Non-small Cell Lung Cancer Therapeutics Revenue, (US$, Mn), 2021 & 2028
Table 15. By Application - Non-small Cell Lung Cancer Therapeutics Revenue in Global (US$, Mn), 2017-2022
Table 16. By Application - Non-small Cell Lung Cancer Therapeutics Revenue in Global (US$, Mn), 2023-2028
Table 17. By Region – Global Non-small Cell Lung Cancer Therapeutics Revenue, (US$, Mn), 2021 & 2028
Table 18. By Region - Global Non-small Cell Lung Cancer Therapeutics Revenue (US$, Mn), 2017-2022
Table 19. By Region - Global Non-small Cell Lung Cancer Therapeutics Revenue (US$, Mn), 2023-2028
Table 20. By Country - North America Non-small Cell Lung Cancer Therapeutics Revenue, (US$, Mn), 2017-2022
Table 21. By Country - North America Non-small Cell Lung Cancer Therapeutics Revenue, (US$, Mn), 2023-2028
Table 22. By Country - Europe Non-small Cell Lung Cancer Therapeutics Revenue, (US$, Mn), 2017-2022
Table 23. By Country - Europe Non-small Cell Lung Cancer Therapeutics Revenue, (US$, Mn), 2023-2028
Table 24. By Region - Asia Non-small Cell Lung Cancer Therapeutics Revenue, (US$, Mn), 2017-2022
Table 25. By Region - Asia Non-small Cell Lung Cancer Therapeutics Revenue, (US$, Mn), 2023-2028
Table 26. By Country - South America Non-small Cell Lung Cancer Therapeutics Revenue, (US$, Mn), 2017-2022
Table 27. By Country - South America Non-small Cell Lung Cancer Therapeutics Revenue, (US$, Mn), 2023-2028
Table 28. By Country - Middle East & Africa Non-small Cell Lung Cancer Therapeutics Revenue, (US$, Mn), 2017-2022
Table 29. By Country - Middle East & Africa Non-small Cell Lung Cancer Therapeutics Revenue, (US$, Mn), 2023-2028
Table 30. GlaxoSmithKline Corporate Summary
Table 31. GlaxoSmithKline Non-small Cell Lung Cancer Therapeutics Product Offerings
Table 32. GlaxoSmithKline Non-small Cell Lung Cancer Therapeutics Revenue (US$, Mn), (2017-2022)
Table 33. Novartis Corporate Summary
Table 34. Novartis Non-small Cell Lung Cancer Therapeutics Product Offerings
Table 35. Novartis Non-small Cell Lung Cancer Therapeutics Revenue (US$, Mn), (2017-2022)
Table 36. AstraZeneca Corporate Summary
Table 37. AstraZeneca Non-small Cell Lung Cancer Therapeutics Product Offerings
Table 38. AstraZeneca Non-small Cell Lung Cancer Therapeutics Revenue (US$, Mn), (2017-2022)
Table 39. Roche Corporate Summary
Table 40. Roche Non-small Cell Lung Cancer Therapeutics Product Offerings
Table 41. Roche Non-small Cell Lung Cancer Therapeutics Revenue (US$, Mn), (2017-2022)
Table 42. Bristol-Myers Squibb Corporate Summary
Table 43. Bristol-Myers Squibb Non-small Cell Lung Cancer Therapeutics Product Offerings
Table 44. Bristol-Myers Squibb Non-small Cell Lung Cancer Therapeutics Revenue (US$, Mn), (2017-2022)
Table 45. Pfizer Corporate Summary
Table 46. Pfizer Non-small Cell Lung Cancer Therapeutics Product Offerings
Table 47. Pfizer Non-small Cell Lung Cancer Therapeutics Revenue (US$, Mn), (2017-2022)
Table 48. Eli Lilly Corporate Summary
Table 49. Eli Lilly Non-small Cell Lung Cancer Therapeutics Product Offerings
Table 50. Eli Lilly Non-small Cell Lung Cancer Therapeutics Revenue (US$, Mn), (2017-2022)
Table 51. Sanofi Corporate Summary
Table 52. Sanofi Non-small Cell Lung Cancer Therapeutics Product Offerings
Table 53. Sanofi Non-small Cell Lung Cancer Therapeutics Revenue (US$, Mn), (2017-2022)

List of Figures
Figure 1. Non-small Cell Lung Cancer Therapeutics Segment by Type in 2021
Figure 2. Non-small Cell Lung Cancer Therapeutics Segment by Application in 2021
Figure 3. Global Non-small Cell Lung Cancer Therapeutics Market Overview: 2021
Figure 4. Key Caveats
Figure 5. Global Non-small Cell Lung Cancer Therapeutics Market Size: 2021 VS 2028 (US$, Mn)
Figure 6. Global Non-small Cell Lung Cancer Therapeutics Revenue, 2017-2028 (US$, Mn)
Figure 7. The Top 3 and 5 Players Market Share by Non-small Cell Lung Cancer Therapeutics Revenue in 2021
Figure 8. By Type - Global Non-small Cell Lung Cancer Therapeutics Revenue Market Share, 2017-2028
Figure 9. By Application - Global Non-small Cell Lung Cancer Therapeutics Revenue Market Share, 2017-2028
Figure 10. By Region - Global Non-small Cell Lung Cancer Therapeutics Revenue Market Share, 2017-2028
Figure 11. By Country - North America Non-small Cell Lung Cancer Therapeutics Revenue Market Share, 2017-2028
Figure 12. US Non-small Cell Lung Cancer Therapeutics Revenue, (US$, Mn), 2017-2028
Figure 13. Canada Non-small Cell Lung Cancer Therapeutics Revenue, (US$, Mn), 2017-2028
Figure 14. Mexico Non-small Cell Lung Cancer Therapeutics Revenue, (US$, Mn), 2017-2028
Figure 15. By Country - Europe Non-small Cell Lung Cancer Therapeutics Revenue Market Share, 2017-2028
Figure 16. Germany Non-small Cell Lung Cancer Therapeutics Revenue, (US$, Mn), 2017-2028
Figure 17. France Non-small Cell Lung Cancer Therapeutics Revenue, (US$, Mn), 2017-2028
Figure 18. U.K. Non-small Cell Lung Cancer Therapeutics Revenue, (US$, Mn), 2017-2028
Figure 19. Italy Non-small Cell Lung Cancer Therapeutics Revenue, (US$, Mn), 2017-2028
Figure 20. Russia Non-small Cell Lung Cancer Therapeutics Revenue, (US$, Mn), 2017-2028
Figure 21. Nordic Countries Non-small Cell Lung Cancer Therapeutics Revenue, (US$, Mn), 2017-2028
Figure 22. Benelux Non-small Cell Lung Cancer Therapeutics Revenue, (US$, Mn), 2017-2028
Figure 23. By Region - Asia Non-small Cell Lung Cancer Therapeutics Revenue Market Share, 2017-2028
Figure 24. China Non-small Cell Lung Cancer Therapeutics Revenue, (US$, Mn), 2017-2028
Figure 25. Japan Non-small Cell Lung Cancer Therapeutics Revenue, (US$, Mn), 2017-2028
Figure 26. South Korea Non-small Cell Lung Cancer Therapeutics Revenue, (US$, Mn), 2017-2028
Figure 27. Southeast Asia Non-small Cell Lung Cancer Therapeutics Revenue, (US$, Mn), 2017-2028
Figure 28. India Non-small Cell Lung Cancer Therapeutics Revenue, (US$, Mn), 2017-2028
Figure 29. By Country - South America Non-small Cell Lung Cancer Therapeutics Revenue Market Share, 2017-2028
Figure 30. Brazil Non-small Cell Lung Cancer Therapeutics Revenue, (US$, Mn), 2017-2028
Figure 31. Argentina Non-small Cell Lung Cancer Therapeutics Revenue, (US$, Mn), 2017-2028
Figure 32. By Country - Middle East & Africa Non-small Cell Lung Cancer Therapeutics Revenue Market Share, 2017-2028
Figure 33. Turkey Non-small Cell Lung Cancer Therapeutics Revenue, (US$, Mn), 2017-2028
Figure 34. Israel Non-small Cell Lung Cancer Therapeutics Revenue, (US$, Mn), 2017-2028
Figure 35. Saudi Arabia Non-small Cell Lung Cancer Therapeutics Revenue, (US$, Mn), 2017-2028
Figure 36. UAE Non-small Cell Lung Cancer Therapeutics Revenue, (US$, Mn), 2017-2028
Figure 37. GlaxoSmithKline Non-small Cell Lung Cancer Therapeutics Revenue Year Over Year Growth (US$, Mn) & (2017-2022)
Figure 38. Novartis Non-small Cell Lung Cancer Therapeutics Revenue Year Over Year Growth (US$, Mn) & (2017-2022)
Figure 39. AstraZeneca Non-small Cell Lung Cancer Therapeutics Revenue Year Over Year Growth (US$, Mn) & (2017-2022)
Figure 40. Roche Non-small Cell Lung Cancer Therapeutics Revenue Year Over Year Growth (US$, Mn) & (2017-2022)
Figure 41. Bristol-Myers Squibb Non-small Cell Lung Cancer Therapeutics Revenue Year Over Year Growth (US$, Mn) & (2017-2022)
Figure 42. Pfizer Non-small Cell Lung Cancer Therapeutics Revenue Year Over Year Growth (US$, Mn) & (2017-2022)
Figure 43. Eli Lilly Non-small Cell Lung Cancer Therapeutics Revenue Year Over Year Growth (US$, Mn) & (2017-2022)
Figure 44. Sanofi Non-small Cell Lung Cancer Therapeutics Revenue Year Over Year Growth (US$, Mn) & (2017-2022)

Report Title: Non-small Cell Lung Cancer Therapeutics Market - Global Outlook and Forecast 2022-2028


Your Details
Valid Invalid number

SELECT A FORMAT

ADD TO CART BUY NOW